Nasopharyngeal Carcinoma Clinical Trials

87 recruiting

Nasopharyngeal Carcinoma Trials at a Glance

141 actively recruiting trials for nasopharyngeal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 50 trials, with the heaviest enrollment activity in Guangzhou, Nanning, and Nanchang. Lead sponsors running nasopharyngeal carcinoma studies include Sun Yat-sen University, Ming-Yuan Chen, and Jiangxi Provincial Cancer Hospital.

Browse nasopharyngeal carcinoma trials by phase

Treatments under study

About Nasopharyngeal Carcinoma Clinical Trials

Looking for clinical trials for Nasopharyngeal Carcinoma? There are currently 87 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nasopharyngeal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nasopharyngeal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 141 trials

Recruiting
Phase 2

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Not Applicable

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Nasopharyngeal CancerNasopharyngeal CarcinomaStage III Nasopharyngeal Carcinoma AJCC v8+2 more
University of California, San Francisco66 enrolled1 locationNCT06682442
Recruiting
Phase 2

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled78 locationsNCT06029270
Recruiting
Phase 2

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)50 enrolled92 locationsNCT05904080
Recruiting
Phase 3

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sun Yat-sen University188 enrolled1 locationNCT04944914
Recruiting
Phase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology98 enrolled149 locationsNCT06532279
Recruiting
Not Applicable

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8+30 more
Emory University118 enrolled1 locationNCT06662058
Recruiting
Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled5 locationsNCT06980038
Recruiting

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Carcinoma of Unknown PrimaryMetastatic Malignant Neoplasm in the Uterine CervixClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+28 more
M.D. Anderson Cancer Center471 enrolled1 locationNCT03010150
Recruiting
Phase 2

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
National Cancer Centre, Singapore53 enrolled2 locationsNCT06093061
Recruiting
Early Phase 1

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Fudan University24 enrolled1 locationNCT05587543
Recruiting
Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting
Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University266 enrolled1 locationNCT07459296
Recruiting
Not Applicable

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center52 enrolled2 locationsNCT07412314
Recruiting
Phase 3

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma
Sun Yat-sen University593 enrolled26 locationsNCT06239727
Recruiting
Phase 3

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University180 enrolled1 locationNCT07327216
Recruiting
Phase 1

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+20 more
Emory University40 enrolled2 locationsNCT06868433
Recruiting
Phase 2

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Nasopharyngeal Carcinoma
Chongqing University Cancer Hospital30 enrolled1 locationNCT06059261
Recruiting
Phase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+19 more
Emory University28 enrolled2 locationsNCT06636734
Recruiting
Phase 2

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Nasopharyngeal Carcinoma
Stanford University24 enrolled1 locationNCT06592599